Overview
Hims & Hers is the largest telehealth platform in the United States, and their entry into the peptide market is the single most significant development in making peptide therapy mainstream. Founded in 2017 as an online health platform, they went public in 2021 and now serve millions of patients across dozens of health categories.
Their peptide offering is currently limited to semaglutide and tirzepatide - both GLP-1 receptor agonists for weight management. But the strategic trajectory is clear: in 2025, Hims & Hers acquired a dedicated peptide manufacturing facility, and their February 2026 earnings call confirmed plans to expand the peptide lineup. When a company with this scale (annual revenue exceeding $1 billion) enters the peptide space, it changes the market dynamics for everyone.
The current GLP-1 pricing of $199-299/month is already competitive with specialized clinics, and the scale advantages of their manufacturing and distribution infrastructure suggest prices could drop further. Their free online consultation model eliminates the cost barrier that slows onboarding at smaller clinics.
The trade-off is clear: Hims offers the most frictionless experience but the narrowest peptide selection. Their 3.5-star Trustpilot rating across 7,850 reviews reflects the challenges of operating at massive scale - some patients report generic customer service experiences. For specialized peptide protocols beyond GLP-1 drugs, other clinics on this list offer broader compound access.
Hims operates in all 50 states, which is a significant advantage over most peptide clinics that face state-by-state licensing restrictions. Their insurance partnerships are developing, and HSA/FSA payments are accepted for certain products.
Best for: Patients seeking semaglutide or tirzepatide for weight management who want the lowest-friction, most accessible entry point into prescribed peptide therapy. Not ideal for patients needing recovery, growth hormone, or niche compounds.
Key Details
Peptides Available (2)
Notable Features
- +Largest US telehealth platform
- +Owns peptide manufacturing facility (acquired 2025)
- +Expanding peptide lineup in 2026
- +Massive scale = lower prices
- +Free online consultations
- +Insurance partnerships developing
Strengths
- +Largest telehealth platform in the US - proven infrastructure
- +Available in all 50 states
- +Competitive GLP-1 pricing ($199-299/month)
- +Free online consultations
- +Owns peptide manufacturing facility (scale advantage)
- +Insurance partnerships developing
Weaknesses
- -Only 2 peptides currently (semaglutide, tirzepatide)
- -3.5-star rating reflects scale challenges in customer service
- -Not specialized in peptide therapy - general telehealth platform
- -No recovery, growth hormone, or anti-aging peptides yet
Frequently Asked Questions
Does Hims offer peptides?
Currently Hims & Hers prescribes semaglutide and tirzepatide for weight management. They acquired a peptide manufacturing facility in 2025 and have announced plans to expand their peptide lineup throughout 2026.
How much does Hims semaglutide cost?
Hims semaglutide pricing ranges from $199-299/month, which is competitive with specialized peptide clinics. Exact pricing depends on dosage and subscription plan.
Is Hims available in all states?
Yes. Hims & Hers operates in all 50 US states, which is a significant advantage over most peptide clinics that face state-by-state licensing restrictions.
Does Hims accept insurance?
Hims & Hers has been developing insurance partnerships. Some plans may partially cover GLP-1 medications. HSA and FSA accounts are accepted. Check their website for current insurance coverage details.
How is Hims different from peptide-specific clinics?
Hims is a general telehealth platform that now offers peptides - primarily GLP-1 weight loss drugs. Peptide-specific clinics like Defy Medical or Peter MD offer broader compound selection (BPC-157, CJC-1295, etc.) and deeper specialization. Hims wins on accessibility and price; specialized clinics win on compound variety and peptide-specific expertise.
Will Hims add more peptides?
Based on their 2025 acquisition of a peptide manufacturing facility and public earnings call statements, Hims plans to expand their peptide offerings in 2026. The specific compounds and timeline have not been publicly confirmed.
Is the Hims consultation really free?
Yes. Hims offers free online consultations for their weight management programs. A licensed provider reviews your health information and determines if treatment is appropriate. You only pay if prescribed medication.
How does Hims semaglutide compare to branded Wegovy?
Hims prescribes compounded semaglutide, which contains the same active ingredient as Wegovy but is produced by compounding pharmacies rather than Novo Nordisk. Compounded versions are typically significantly less expensive than branded Wegovy.